MD236G2 - Tablets "Cimpelsept" and method of their preparation - Google Patents

Tablets "Cimpelsept" and method of their preparation

Info

Publication number
MD236G2
MD236G2 MD95-0175A MD950175A MD236G2 MD 236 G2 MD236 G2 MD 236G2 MD 950175 A MD950175 A MD 950175A MD 236 G2 MD236 G2 MD 236G2
Authority
MD
Moldova
Prior art keywords
tablets
mass
added
volatile
aspartam
Prior art date
Application number
MD95-0175A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD236F1 (en
Inventor
Еуджен ДЮГ
Виорел ПРИСАКАРЬ
Mihai Bodrug
Original Assignee
Intreprinderea Individuala "Medifarm-Diug"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intreprinderea Individuala "Medifarm-Diug" filed Critical Intreprinderea Individuala "Medifarm-Diug"
Priority to MD95-0175A priority Critical patent/MD236G2/en
Publication of MD236F1 publication Critical patent/MD236F1/en
Publication of MD236G2 publication Critical patent/MD236G2/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The tablets “Cimpelsept” contain as active principals the volatile oil of chimbr mountain and wormwood citric and as a replenisher microcrystalline cellulose pectin, lactose, calcium sfearat, are also supplementary contained organoliptic components - menthol and aspartam at the following ratio of components (mass %):The offered tablets provide effective sanation (65-81,3%) of the mouth cavity of the staphylococcus germ-carriers, in addition they donate effect of the exasperating action on the mucous membranes.The method of tablet preparation foresees the mixture of volatile oils with microcrystalline cellulose at a temperature of 10-20°C, after that lactose and pectin are added, all mass is mixed during not less than 10 min., the mixture of aspartam are added, menthol and calcium stearat are added, all mass are remixed not less than 10 min. and carry out the pressure at 588-882 N. Such embodiment of method makes possible to provide the greatest state of oils volatile preservation in tablets and their disintegration in the mouth cavity during 27-50 min.
MD95-0175A 1995-01-20 1995-01-20 Tablets "Cimpelsept" and method of their preparation MD236G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MD95-0175A MD236G2 (en) 1995-01-20 1995-01-20 Tablets "Cimpelsept" and method of their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MD95-0175A MD236G2 (en) 1995-01-20 1995-01-20 Tablets "Cimpelsept" and method of their preparation

Publications (2)

Publication Number Publication Date
MD236F1 MD236F1 (en) 1995-07-31
MD236G2 true MD236G2 (en) 1995-12-31

Family

ID=19738635

Family Applications (1)

Application Number Title Priority Date Filing Date
MD95-0175A MD236G2 (en) 1995-01-20 1995-01-20 Tablets "Cimpelsept" and method of their preparation

Country Status (1)

Country Link
MD (1) MD236G2 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Barbaroşie I., Diug E., Ciobanu N. Tehnologia medicamentelor industriale, Chişinău, Ştiinţa, 1993, p. 387-399 *
Машковский М.Д. Лекарственные средства. Часть 2, М., Медицина, 1993, с. 388 *
Машковский М.Д. Лекартсвенные средства. . Часть 2, М., Медицина, 1993, с. 400 *

Also Published As

Publication number Publication date
MD236F1 (en) 1995-07-31

Similar Documents

Publication Publication Date Title
MY129281A (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of a acute condition of asthma
UA41369C2 (en) NICOTINE TABLET AND METHOD OF TREATMENT FROM SMOKING
BR0003158A (en) Instant melting oral dosage formulation
ES2157566T3 (en) PROCESS FOR MANUFACTURING A NICE TASTE MEDICINAL CHICLE THAT CONTAINS AN INCLUSION COMPLEX.
KR100197465B1 (en) Rapidly disintegratable multiparticulate tablet
AU1537095A (en) Therapeutic agents containing thyroid hormones
ES8505817A1 (en) Two-phase formulation.
NO20050379L (en) Use of venlafaxine hydrochloride for the preparation of an encapsulated extended release mixture
HUT77702A (en) Vitamin and calcium therapeutic combination in the form of a single galenic tablet, for the preparation and application of a method
AU5683796A (en) Novel pharmaceutical pellet formulation
WO1998006868A3 (en) Production and use of compositions comprising high concentrations of vitamin b12 activity
KR880003620A (en) Therapeutic Composition and Method
MY114716A (en) Prophylactic and/or therapeutic treatment of dyspeptic symptoms
ID21038A (en) TABLETS THAT CONTAIN ANION EXCHANGE RESIN
JPS52130922A (en) Remedy for cerebral blood flow disorders containing coenzyme-q as main ingredient
MD236G2 (en) Tablets "Cimpelsept" and method of their preparation
JPS6434926A (en) Local drug and/or cosmetic composition containing ramsan rubber
HU9602470D0 (en) Tablets containing captopril and process for producing them
GR74171B (en)
TNSN94110A1 (en) PROCESS FOR THE PREPARATION OF ORAL COMPOSITIONS CONTAINING QUINOLONES
KR980700083A (en) Kit for Osteoporosis Treatment Cycle
DE69729729D1 (en) MEDICINES FOR USE IN THE MOUTH
JPS643123A (en) Remedy for skin inflammation
MX9606354A (en) Sublingual formulation of ketorolac.
CA2123853A1 (en) Smoking Suppressant and Method of Application Thereof